OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen Sells 5,310 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now directly owns 110,767 shares in the company, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

OrthoPediatrics Stock Up 1.8 %

Shares of OrthoPediatrics stock opened at $25.42 on Wednesday. The stock’s fifty day moving average is $24.79 and its 200-day moving average is $25.53. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 12-month low of $21.02 and a 12-month high of $35.99. The firm has a market capitalization of $617.38 million, a PE ratio of -20.67 and a beta of 1.22.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.67 million for the quarter, compared to the consensus estimate of $51.16 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. Equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Institutional Investors Weigh In On OrthoPediatrics

A number of hedge funds have recently bought and sold shares of KIDS. Quarry LP acquired a new stake in OrthoPediatrics in the 3rd quarter valued at approximately $25,000. R Squared Ltd acquired a new stake in OrthoPediatrics during the fourth quarter worth about $48,000. KLP Kapitalforvaltning AS acquired a new stake in OrthoPediatrics during the fourth quarter worth about $79,000. BNP Paribas Financial Markets grew its position in OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after buying an additional 1,929 shares in the last quarter. Finally, Quantbot Technologies LP grew its position in OrthoPediatrics by 42.2% during the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock worth $157,000 after buying an additional 1,712 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on KIDS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 price target on shares of OrthoPediatrics in a report on Wednesday, March 5th. Truist Financial cut their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Stifel Nicolaus cut their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.